Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

StatusActive, Not Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Sep 1, 2025 to Dec 11, 2025
    • Study completion pushed from Dec 1, 2039 to Dec 1, 2040
    • Eligibility criteria expanded, about 27 words
  2. Trial status: Suspended to Active, Not Recruiting
    • Enrollment target: estimated 36 to confirmed 18
    v11
  3. Primary completion date: Mar 1, 2025 to Sep 1, 2025v10
  4. Trial status: Recruiting to Suspended Sponsor's reason: Vector expired
    • Site details revised
    v9
  5. Primary completion date: Jun 1, 2024 to Mar 1, 2025
    • Study completion date: Dec 1, 2024 to Dec 1, 2039
    • Site contact updated
    • Eligibility criteria expanded, about 5 words
    v8
Show 6 earlier versionsHide 6 earlier versions
  1. Primary completion date: Jun 2023 to Jun 1, 2024
    • Study completion date: Dec 2023 to Dec 1, 2024
    v7
  2. Eligibility criteria shortened, about 9 wordsv6
  3. Eligibility criteria expanded, about 1 wordv5
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 2021 to Apr 26, 2021
    • Site details revised
    v4
  5. Lead sponsor: Paolo Caimi, MD to Benjamin Tomlinson
    • Site contact updated
    v3
  6. Start date: Feb 2021 to Sep 2021v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Benjamin Tomlinson
4 trials monitored
See 1 trial at risk
Leukemia
2,957 trials monitored
See 176 trials at risk
Non-Hodgkin Lymphoma
2,017 trials monitored
See 114 trials at risk
Acute Lymphoblastic Leukemia (ALL)
934 trials monitored
See 55 trials at risk
and 1 more disease
The purpose of this study is to determine if it is possible to treat relapsed or refractory lymphoid malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia) with a new type of T cell-based immunotherapy (therapy that uses the immune system to treat the cancer).
Trial Details
NCT Number NCT04732845
Lead Sponsor Benjamin Tomlinson
Conditions
(from sponsor)		 Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia
Related terms Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov